- Report
- February 2026
- 180 Pages
Global
From €4409EUR$4,850USD£3,790GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- September 2026
- 184 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 282 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- August 2026
- 117 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- May 2024
- 131 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- July 2021
- 50 Pages
China
From €2363EUR$2,600USD£2,032GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,125USD£3,115GBP
- Report
- September 2026
- 50 Pages
Global
From €2409EUR$2,650USD£2,071GBP
- Report
- March 2025
- 109 Pages
China
From €1636EUR$1,800USD£1,407GBP
- Report
- March 2025
- 215 Pages
China
From €3636EUR$4,000USD£3,126GBP

Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more